Bisfosfonaten en de indicatie implantologie

Bisfosfonaten worden onder meer voorgeschreven bij aandoeningen als osteoporose, botmetastasen en de ziekte van Kahler. In een literatuuronderzoek stond de vraag centraal of het gebruik van bisfosfonaten een contra-indicatie is voor implanteren. De representativiteit van dit onderzoek roept echter vragen op.

Bisphosphonate (BP) drugs are a commonly prescribed group of medications used in the treatment of metabolic and oncologic bone disorders. The aim of this study was to conduct a systematic review in order to evaluate whether patients on BP therapy are appropriate candidates for dental implants as compared to patients not taking BP drugs with respect to successful implant osseointegration and the risk of developing bisphosphonate-related osteonecrosis of the jaw. Based on the current literature, a history of oral or intravenous BP use is not an absolute contraindication for dental implant placement, and dental implants can osseointegrate successfully in this patient population. Importantly, the studies currently available on this topic are of moderate to weak strength of evidence with inherent bias and limitations, and hence results must be interpreted in this context. Well-controlled studies with higher strength of evidence and larger population sizes are required to address this topic more accurately in the future.

Bron

Chadha GK, Ahmadieh A, Kumar S, Sedghizadeh PP. Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review. J Oral Implantol 2013; 4: 510-520. doi: 10.1563/AAID-JOI-D-11-00234.